"The company#39;s formulations manufacturing facility located at Baddi, India, has received an EIR. The United States Food and Drug Administration (USFDA) had conducted an inspection at the facility from July 15 to 19, 2019," Cadila Healthcare said in a filing to BSE.from Moneycontrol Business News https://ift.tt/2N1stW1
No comments:
Post a Comment